These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 25374716)

  • 1. Death from Liver Failure despite Lamivudine Prophylaxis during R-CHOP Chemotherapy due to Rapid Emergence M204 Mutations.
    Win LL; Powis J; Shah H; Feld JJ; Wong DK
    Case Reports Hepatol; 2013; 2013():454897. PubMed ID: 25374716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lamivudine 24-month-long prophylaxis is a safe and efficient choice for the prevention of hepatitis B virus reactivation in HBsAg-negative/HBcAb-positive patients with advanced DLBCL undergoing upfront R-CHOP-21.
    Giordano C; Picardi M; Pugliese N; Vincenzi A; Abagnale DP; De Fazio L; Giannattasio ML; Fatigati C; Ciriello M; Salemme A; Muccioli Casadei G; Vigliar E; Mascolo M; Troncone G; Pane F
    Front Oncol; 2023; 13():1130899. PubMed ID: 36890828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
    Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
    Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Effect of Prophylactic Lamivudine plus Adefovir Therapy Compared with Lamivudine Alone in Preventing Hepatitis B Reactivation in Lymphoma Patients with High Baseline HBV DNA during Chemotherapy.
    Cai Q; Chen K; Chen J; Wu S; Geng Q; Huang H; Lin T; Jiang W; Xia Z; Duan H; Rao H; Yao M; Hu L
    PLoS One; 2016; 11(10):e0164210. PubMed ID: 27711135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical prediction of failure of Lamivudine prophylaxis for hepatitis B virus-infected patients undergoing cytotoxic chemotherapy for malignancy.
    Kim IK; Kim BG; Kim W; Kim D; Kim YJ; Yoon JH; Lee HS
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5511-9. PubMed ID: 22890764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.
    Dai MS; Chao TY; Kao WY; Shyu RY; Liu TM
    Ann Hematol; 2004 Dec; 83(12):769-74. PubMed ID: 15338194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of chronic hepatitis B: case selection and duration of therapy.
    Leung N
    J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tenofovir rescue therapy in chronic hepatitis B patients who failed previous nucleoside analogue treatment.
    Kozielewicz D; Halota W; Wietlicka-Piszcz M
    Hepatol Int; 2016 Mar; 10(2):302-9. PubMed ID: 26612013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B.
    Patterson SJ; George J; Strasser SI; Lee AU; Sievert W; Nicoll AJ; Desmond PV; Roberts SK; Locarnini S; Bowden S; Angus PW
    Gut; 2011 Feb; 60(2):247-54. PubMed ID: 21036792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Core promoter mutant HBV non-responding to adefovir after viral breakthrough on lamivudine: rapid virologic response to tenofovir plus lamivudine in a cirrhotic patient.
    Katsounas A; Jochum C; Canbay A; Schlaak J; Gerlich WH; Gerken G
    Eur J Med Res; 2008 Oct; 13(10):472-5. PubMed ID: 19008175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of lamivudine prophylaxis in preventing hepatitis B virus reactivation in patients with resolved infection undergoing allogeneic SCT and receiving rituximab.
    Zappulo E; Nicolini LA; Di Grazia C; Dominietto A; Lamparelli T; Gualandi F; Caligiuri P; Bruzzone B; Angelucci E; Viscoli C; Mikulska M
    Infection; 2019 Feb; 47(1):59-65. PubMed ID: 30232604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients.
    Kosi L; Reiberger T; Payer BA; Grabmeier-Pfistershammer K; Strassl R; Rieger A; Peck-Radosavljevic M
    J Viral Hepat; 2012 Nov; 19(11):801-10. PubMed ID: 23043387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Comparison of Entecavir and Lamivudine for the Prophylaxis of Hepatitis B Virus Reactivation in Solid Tumor Patients Undergoing Systemic Cytotoxic Chemotherapy.
    Chen WC; Cheng JS; Chiang PH; Tsay FW; Chan HH; Chang HW; Yu HC; Tsai WL; Lai KH; Hsu PI
    PLoS One; 2015; 10(6):e0131545. PubMed ID: 26121480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.
    Huang H; Li X; Zhu J; Ye S; Zhang H; Wang W; Wu X; Peng J; Xu B; Lin Y; Cao Y; Li H; Lin S; Liu Q; Lin T
    JAMA; 2014 Dec; 312(23):2521-30. PubMed ID: 25514302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic use of low-dose, on-demand, intramuscular hepatitis B immunoglobulin and lamivudine after liver transplantation.
    Karademir S; Astarcioğlu H; Akarsu M; Ozkardesler S; Ozzeybek D; Sayiner A; Akan M; Tankurt E; Astarcioğlu I
    Transplant Proc; 2006 Mar; 38(2):579-83. PubMed ID: 16549180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The optimal threshold: Baseline serum hepatitis B virus DNA and alanine transaminase levels can predict the 2-Year on-treatment virological response to lamivudine.
    Yan J; Xie W; Wang Q; Li Y; Feng X; Cheng J
    Hepat Mon; 2011 May; 11(5):358-63. PubMed ID: 22087161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective.
    Wesdorp DJ; Knoester M; Braat AE; Coenraad MJ; Vossen AC; Claas EC; van Hoek B
    J Clin Virol; 2013 Sep; 58(1):67-73. PubMed ID: 23880162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urgent liver transplantation for chemotherapy-induced HBV reactivation: a suitable option in patients recently treated for malignant lymphoma.
    Sperl J; Frankova S; Kieslichova E; Oliverius M; Janousek L; Honsova E; Trunecka P; Spicak J
    Transplant Proc; 2013 Sep; 45(7):2834-7. PubMed ID: 24034061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates.
    Gane EJ; Patterson S; Strasser SI; McCaughan GW; Angus PW
    Liver Transpl; 2013 Mar; 19(3):268-74. PubMed ID: 23447403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Maternal-fetal outcomes of lamivudine treatment administered during late pregnancy to highly viremic mothers with HBeAg+ chronic hepatitis B].
    Jiang HX; Han GR; Wang CM; Ji Y
    Zhonghua Gan Zang Bing Za Zhi; 2012 Dec; 20(12):888-91. PubMed ID: 23522247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.